Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 122.00
Bid: 121.40
Ask: 122.00
Change: 1.60 (1.33%)
Spread: 0.60 (0.494%)
Open: 121.00
High: 122.00
Low: 120.40
Prev. Close: 120.40
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS: Gym Group directors sell GBP1.8 million in shares

Tue, 30th Mar 2021 16:01

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Tuesday and not separately reported by Alliance News:

----------

Gym Group PLC - Croydon-based gym chain - Founder Director John Treharne sells 500,000 shares and Senior Independent Director Paul Gilbert sells 204,442 shares, both at 251.75 pence and together worth GBP1.8 million, on Monday. Treharne retains 2.1 million shares, while Gilbert sold his entire shareholding, as he is retiring from the board at the next annual general meeting.

----------

Anpario PLC - Nottinghamshire-based animal feed additives - Chief Executive Officer Richard Edwards sells 125,000 shares at 580p, worth GBP725,000, on Monday. Now has 88,396 shares, a 0.4% stake.

----------

NatWest Group PLC - Edinburgh-based lender - Robert Begbie, CEO of investment banking division NatWest Markets, sells 25,007 shares at GBP1.91, worth GBP47,791, on Monday.

----------

CVS Group PLC - Norfolk, England-based veterinary services - Non-Executive Director Richard Gray and wife Jennifer Gray buy 3,000 shares at 1,872 pence, worth GBP56,160. The purchase is Gray's only holding, having joined the CVS board in July last year.

----------

Syncona Ltd - investor in life science companies - Three non-executive directors - Virginia Holmes, Gianpiero Reverberi and Kemal Malik - buy 59,475 shares in total, at about GBP2.61 per share, worth GBP155,230, on Friday last week.

----------

Learning Technologies Group PLC - London-based digital learning services provider - Non-Executive Director Leslie-Ann Reed buys 100,000 shares at average GBP1.54, worth GBP154,000, on Monday. Reed now has 4.9 million shares, a 0.7% stake.

----------

Forterra PLC - Northampton, England-headquartered building products manufacturer - Chief Financial Officer Ben Guyatt sells 23,128 shares at GBP2.86, worth GBP66,249, while his spouse Wendy Guyatt buys 6,897 shares at GBP2.88, both on Monday. Guyatt now interested in 35,217 shares.

----------

LXi REIT PLC - London-based real estate investment trust - Non-Executive Director Colin Smith buys 25,000 shares at 122.3p, worth GBP30,575, on Monday. Now has 247,909 shares.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
26 Mar 2021 09:20

Syncona invests USD42 million into Gyroscope to have 54% stake

Syncona invests USD42 million into Gyroscope to have 54% stake

Read more
26 Mar 2021 07:59

Syncona invests £31m in Gyroscope

(Sharecast News) - Syncona has invested $42.3m (£31m) in Gyroscope Therapeutics as part of a $148m financing by the retinal gene therapy company.

Read more
25 Mar 2021 12:23

Syncona portfolio firm Achilles Therapeutics prices US share offering

Syncona portfolio firm Achilles Therapeutics prices US share offering

Read more
4 Mar 2021 12:46

TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance

TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance

Read more
2 Mar 2021 13:45

IN BRIEF: Syncona investee Achilles Therapeutics files for US IPO

IN BRIEF: Syncona investee Achilles Therapeutics files for US IPO

Read more
12 Feb 2021 16:24

IN BRIEF: Syncona's Gyroscope Reports Positive Results From GT005 Test

IN BRIEF: Syncona's Gyroscope Reports Positive Results From GT005 Test

Read more
11 Feb 2021 10:05

Syncona Net Asset Value Dips In Third Quarter, Invests More In Quell

Syncona Net Asset Value Dips In Third Quarter, Invests More In Quell

Read more
11 Feb 2021 07:56

Syncona makes decent progress in December quarter

(Sharecast News) - Healthcare investment company Syncona updated the market on its latest quarter on Thursday, reporting clinical, financial and operational progress across its portfolio in the three months ended 31 December.

Read more
10 Feb 2021 09:41

Syncona Investee Autolus Nets USD100 Million From ADS Offer

Syncona Investee Autolus Nets USD100 Million From ADS Offer

Read more
10 Feb 2021 09:31

Syncona upbeat on Autolus US public offering pricing

(Sharecast News) - Healthcare investor Syncona said on Wednesday that its portfolio company Autolus Therapeutics has priced its underwritten public offering in the United States at $7.00 per American depositary share (ADS).

Read more
8 Feb 2021 13:09

Syncona Investee Freeline Modifies Hemophilia Plan After FDA Feedback

Syncona Investee Freeline Modifies Hemophilia Plan After FDA Feedback

Read more
5 Feb 2021 08:20

Syncona Investee Achilles Reports Positive Trial Review, Mulling IPO

Syncona Investee Achilles Reports Positive Trial Review, Mulling IPO

Read more
5 Feb 2021 08:01

Syncona investment Achilles upbeat on safety review of trials

(Sharecast News) - Healthcare investor Syncona said on Friday that its portfolio company Achilles Therapeutics, which is developing precision T-cell therapies to treat solid tumours, had announced that an independent data and safety monitoring committee had completed the first review of the ongoing, first-in-human phase 1 and 2 'CHIRON' and 'THETIS' trials.

Read more
6 Jan 2021 09:30

Syncona Investee Autolus To Focus On Adult Leukemia Programme in 2021

Syncona Investee Autolus To Focus On Adult Leukemia Programme in 2021

Read more
6 Jan 2021 08:36

Syncona upbeat on developments at Autolus

(Sharecast News) - Life science investor Syncona updated the market on its portfolio company Autolus on Wednesday, announcing that it would prioritise the development of the 'AUTO1' programme for adult acute lymphoblastic leukemia (ALL), based on the positive data generated in its phase 1 and 2 studies to date and a high unmet medical need.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.